Online inquiry

IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9731MR)

This product GTTS-WQ9731MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TFRC gene. The antibody can be applied in Hunter syndrome research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001128148.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7037
UniProt ID P02786
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9731MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7618MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ13282MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ11669MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ4715MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ10036MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA L19-131 I
GTTS-WQ14813MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ9587MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ13390MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1594804
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW